Equity Profile

IMNM

Immunome, Inc.

Health CareBiotechnology$2.6B

Nov4Fri

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Immunome, Inc. is a biotechnology company focused on developing innovative therapies for cancer and other diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to generate sales and is crucial for assessing its market performance.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

IMNM Q2-2026 Earnings Preview

Context

Company Snapshot

Immunome, Inc. is a biotechnology company focused on developing innovative therapies for cancer and other diseases. Operating in the health care sector, its work is significant as it aims to harness the power of the immune system to fight diseases, which is a major theme in modern medicine.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-68.16%

Avg Stock Reaction

-1.95%

Last Quarter Recap

In Q1-2026, Immunome reported an EPS of -$0.48, which was better than the expected -$0.60, resulting in a positive surprise. However, revenue figures were not disclosed, leaving some uncertainty about overall performance.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are cautious ahead of the earnings report, given the company's history of mixed results and lack of guidance. Investors are particularly interested in any updates regarding the company's pipeline and financial metrics.

Bull Case

If Immunome can show progress in its drug development pipeline and report better-than-expected EPS, it could lead to a significant positive reaction from investors.

Bear Case

Conversely, if the company fails to meet expectations or provides disappointing updates on its therapies, it could lead to a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of the drug pipeline and any upcoming clinical trial results?

Updates on the pipeline are critical as they can influence investor confidence and stock performance.

How does the company plan to manage its expenses moving forward?

Understanding expense management is crucial for assessing the company's path to profitability and financial stability.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating the potential of Immunome's pipeline, particularly if recent advancements are not fully reflected in current expectations.

Supporting Evidence

The company's recent EPS surprise indicates better-than-expected performance, which could signal stronger fundamentals.

Options pricing suggests a significant move, indicating that traders are anticipating volatility that could favor the stock.

The historical trend shows that the stock has reacted positively to pipeline updates, which may not be fully accounted for in current sentiment.

Key Risk

If the company provides strong updates on its pipeline, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to advance its drug pipeline while managing costs effectively.

Bull Confirmed If

A positive update on the drug pipeline with at least one upcoming trial showing promising results.

Bear Confirmed If

Any indication of delays or failures in the drug development process.

Pre-Earnings Positioning

Options Market

Implied Move

±44.33%

Historical Avg

±3.8%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±44.3% while IMNM has averaged ±3.8% over the last 8 prints — setup is pricing rich.

Detail

30d HV

54.2%

Calls (11K)P/C Ratio: 5.31Puts (100)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Immunome beats expectations, history suggests a potential stock increase of around +0.50%, confirming positive sentiment around its pipeline.

In-Line / Cautious

If results are in line with expectations, the stock may see limited movement as investors await further clarity on future plans.

Miss

A miss could lead to a decline of approximately -3.42%, reflecting investor disappointment in the company's progress.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on the status of ongoing clinical trials and any upcoming results.
2Management's commentary on cost management strategies.
3Any updates on partnerships or collaborations that could enhance the pipeline.
4Insights into market demand for the therapies being developed.
5Future guidance on revenue expectations and financial health.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Cirrus Logic, Inc.

Company Snapshot

Immunome, Inc. is a biotechnology company focused on developing innovative therapies for cancer and other diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to generate sales and is crucial for assessing its market performance.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

IMNM Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-68.16%

Avg Stock Reaction

-1.95%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Immunome can show progress in its drug development pipeline and report better-than-expected EPS, it could lead to a significant positive reaction from investors.

Bear Case

Conversely, if the company fails to meet expectations or provides disappointing updates on its therapies, it could lead to a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of the drug pipeline and any upcoming clinical trial results?

Updates on the pipeline are critical as they can influence investor confidence and stock performance.

How does the company plan to manage its expenses moving forward?

Understanding expense management is crucial for assessing the company's path to profitability and financial stability.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating the potential of Immunome's pipeline, particularly if recent advancements are not fully reflected in current expectations.

Supporting Evidence

The company's recent EPS surprise indicates better-than-expected performance, which could signal stronger fundamentals.

Options pricing suggests a significant move, indicating that traders are anticipating volatility that could favor the stock.

The historical trend shows that the stock has reacted positively to pipeline updates, which may not be fully accounted for in current sentiment.

Key Risk

If the company provides strong updates on its pipeline, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to advance its drug pipeline while managing costs effectively.

Bull Confirmed If

A positive update on the drug pipeline with at least one upcoming trial showing promising results.

Bear Confirmed If

Any indication of delays or failures in the drug development process.

Pre-Earnings Positioning

Options Market

Implied Move

±44.33%

Historical Avg

±3.8%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±44.3% while IMNM has averaged ±3.8% over the last 8 prints — setup is pricing rich.

Detail

30d HV

54.2%

Calls (11K)P/C Ratio: 5.31Puts (100)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Immunome beats expectations, history suggests a potential stock increase of around +0.50%, confirming positive sentiment around its pipeline.

In-Line / Cautious

If results are in line with expectations, the stock may see limited movement as investors await further clarity on future plans.

Miss

A miss could lead to a decline of approximately -3.42%, reflecting investor disappointment in the company's progress.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on the status of ongoing clinical trials and any upcoming results.
2Management's commentary on cost management strategies.
3Any updates on partnerships or collaborations that could enhance the pipeline.
4Insights into market demand for the therapies being developed.
5Future guidance on revenue expectations and financial health.